COGT vs RVMD
COGT: A clinical-stage biotechnology company developing precision protein kinase inhibitors for oncology and genetically defined diseases. RVMD: Revolution Medicines is a precision oncology company developing targeted therapies to treat RAS-addicted cancers through its proprietary research platform.
Side-by-side fundamentals
| Metric | COGT | RVMD | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $36.73 | $209.46 | |
| Market cap as of 2026-08-24 | $6.4B | $44.9B | |
| PEG as of 2026-08-24 | n/a | -0.25 | |
| Net margin as of 2026-08-24 | -264.1% | -2833.9% | COGT higher |
| Operating margin as of 2026-08-24 | -295.8% | -3145.0% | COGT higher |
| ROE as of 2026-08-24 | -83.3% | -54.1% | RVMD higher |
| ROA as of 2026-08-24 | -55.8% | -39.1% | RVMD higher |
| Debt / equity as of 2026-08-24 | 0.37 | 0.40 | COGT lower |
| Beta as of 2026-08-24 | 0.31 | 1.41 | |
| 1-year return as of 2026-08-21 close | +212.1% | +474.2% | RVMD higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.